Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer

Petris, Luigi De; Orre, Lukas M.; Kanter, Lena; Pernemalm, Maria; Koyi, Hirsh; Lewensohn, Rolf; Lehtiö, Janne

doi:10.1016/j.lungcan.2008.06.003

Cited by 57 publications

(53 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, high levels of S100A6 expression related to a significant decrease in survival time for patients with pancreatic cancer, 28 and in melanoma, a significant correlation was found between S100A6 mRNA levels in metastases and survival time of patients, 32 and in non-small-cell lung cancer, S100A6-positive cases showed a trend of longer survival compared with S100A6-negative cases. 21 And a recent report found that S100A6 was significantly up-regulated in gastric cancers and associated with gastric cancer tumorigenesis. 22 Our finding supported the involvement of S100A6 in the invasion and metastasis of gastric cancer.…”

Section: Discussionmentioning

confidence: 98%

S100A6 Overexpression Is Associated with Poor Prognosis and Is Epigenetically Up-Regulated in Gastric Cancer

Wang

Zhang

Zhong

et al. 2010

The American Journal of Pathology

View full text Add to dashboard Cite

S100A6 has been implicated in a variety of biological functions as well as tumorigenesis. In this study, we investigated the expression status of S100A6 in relation to the clinicopathological features and prognosis of patients with gastric cancer and further explored a possible association of its expression with epigenetic regulation. S100A6 expression was remarkably increased in 67.5% of gastric cancer tissues as compared with matched noncancerous tissues. Statistical analysis demonstrated a clear correlation between high S100A6 expression and various clinicopathological features, such as depth of wall invasion, positive lymph node involvement, liver metastasis, vascular invasion, and tumor-node metastasis stage (P < 0.05 in all cases), as well as revealed that S100A6 is an independent prognostic predictor (P ‫؍‬ 0.026) significantly related to poor prognosis (P ‫؍‬ 0.0004). Further exploration found an inverse relationship between S100A6 expression and the methylation status of the seventh and eighth CpG sites in the promoter/first exon and the second to fifth sites in the second exon/second intron. In addition, the level of histone H3 acetylation was found to be significantly higher in S100A6-expressing cancer cells. After 5-azacytidine or trichostatin A treatment, S100A6 expression was clearly increased in S100A6 low-expressing cells. In conclusion, our results suggested that S100A6 plays an important role in the progression of gastric cancer, affecting patient prognosis, and is up-regulated by epigenetic regulation. (Am J

show abstract

Section: Discussionmentioning

confidence: 98%

S100A6 Overexpression Is Associated with Poor Prognosis and Is Epigenetically Up-Regulated in Gastric Cancer

Wang

Zhang

Zhong

et al. 2010

The American Journal of Pathology

View full text Add to dashboard Cite

show abstract

“…There have been a number of reports on the relationship between S100 proteins (e.g., S100A2, S100A4, and S100A6) and lung cancer [25][26][27][28][29][30][31][32]. Overexpression of S100A9 has been observed in breast cancer, gastric cancer, prostate cancer, hepatocellular carcinoma, and lung cancer [19][20][21][33][34][35], but there have been no studies addressing the clinical significance of S100A9 expression in NSCLC.…”

Section: Discussionmentioning

confidence: 99%

Prognostic impact of S100A9 overexpression in non-small cell lung cancer

2011

View full text Add to dashboard Cite

S100 proteins have been implicated in the progression and metastasis of several cancers. Among the S100 family, S100A9 is reportedly expressed in non-small cell lung cancer (NSCLC), though the clinical significance and prognostic value of S100A9 expression in NSCLC remains unclear. The aim of the present study was to examine the relationship between S100A9 expression and prognosis in NSCLC patients. S100A9 expression was evaluated by immunohistochemical staining. Seventy patients with NSCLC who had undergone lung resection were enrolled in the study. Overexpression of S100A9 was observed in 38 (54.3%) patients. Kaplan-Meier analysis showed that, following surgery, patients overexpressing S100A9 had a significantly lower 5-year overall survival rate than patients with weak or no expression of S100A9 (P=0.005). This finding was also observed in pathological stage IA patients (P=0.03). Multivariate Cox regression analysis revealed overexpression of S100A9 to be an independent factor predictive of poor disease outcome (hazard ratio, 0.3; 95% confidence interval, 0.1-0.8; P=0.02). Our results suggest that overexpression of S100A9 is associated with a poor prognosis among NSCLC patients and could serve as a marker identifying patients who are at high risk, even at an early pathological stage.

show abstract

“…S100A6 is most abundant in epithelial cells and fibroblasts but is also found, in smaller amounts, in other cell-types such as neurons, glial cells, smooth muscle cells, cardiac myocytes, platelets and lymphocytes [215,216](reviewed in [217]). S100A6 has been found elevated in a large number of cancer types which include colorectal cancer, pancreatic, hepato-cellular carcinoma, melanoma, lung cancer and gastric cancer [165,[218][219][220][221][222][223][224](reviewed in [217]). In melanoma tumor samples, a positive correlation was found between the levels of S100A6 transcripts and the severity of the disease [165].…”

Section: S100a6mentioning

confidence: 99%

RAGE and Its Ligands in Melanoma

Leclerc¹

2015

Melanoma - Current Clinical Management and Future Therapeutics

View full text Add to dashboard Cite

Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer

Cited by 57 publications

References 37 publications

S100A6 Overexpression Is Associated with Poor Prognosis and Is Epigenetically Up-Regulated in Gastric Cancer

S100A6 Overexpression Is Associated with Poor Prognosis and Is Epigenetically Up-Regulated in Gastric Cancer

Prognostic impact of S100A9 overexpression in non-small cell lung cancer

RAGE and Its Ligands in Melanoma

Contact Info

Product

Resources

About